Search Medical Condition
Please enter condition
Please choose location from dropdown

Matsuyama-shi, Japan Clinical Trials

A listing of Matsuyama-shi, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (90) clinical trials

Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer

The purpose of study is to compare the efficacy and safety of ONO-4538 in combination with carboplatin, paclitaxel, and bevacizumab (ONO-4538 group) to placebo in combination with carboplatin, paclitaxel, and bevacizumab (placebo group) in chemotherapy-nave subjects with stage IIIB/IV or recurrent non-squamous non-small cell lung cancer unsuitable for radical radiation ...

Phase

0.0 miles

Learn More »

ADYNOVATE Drug Use-Results Survey

The purpose of this survey is to understand the following items in the actual clinical use of ADYNOVATE in patients: Unexpected adverse drug reactions Occurrence of adverse drug reactions in the actual clinical use Factors that may affect safety and efficacy Occurrence of Factor VIII inhibitor development in patients with ...

Phase N/A

0.0 miles

Learn More »

Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Patients With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation

Study AG120-C-009 is a global, Phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of AG-120 (ivosidenib) + azacitidine vs placebo + azacitidine in adult subjects with previously untreated IDH1m AML who are considered appropriate candidates for non-intensive therapy. The primary endpoint is Overall Survival ...

Phase

0.0 miles

Learn More »

Study of Adjuvant ONO-4538 With Resected Gastric Cancer

The purpose of study is to evaluate the efficacy and safety of postoperative adjuvant chemotherapy with Nivolumab in combination with tegafur-gimeracil-oteracil potassium (S-1 therapy) or capecitabine + oxaliplatin (CapeOX therapy), in comparison with placebo in combination with S-1 therapy or CapeOX therapy, in pStage III gastric cancer (including esophagogastric junction ...

Phase

0.0 miles

Learn More »

Phase 2 Study of Brigatinib in Japanese Patients With ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

The drug being tested in this study is called brigatinib. Brigatinib is being tested in patients with ALK-positive NSCLC in order to evaluate efficacy and safety of oral doses of brigatinib in Japanese patients with ALK-positive NSCLC. The study will enroll approximately 110 participants. Participants will be enrolled in non-randomized ...

Phase

0.0 miles

Learn More »

To Evaluate the Efficacy and Safety of FE 999315 in Japanese Subjects With Mild to Moderate Active Ulcerative Colitis

To demonstrate non-inferiority in efficacy of FE 999315 to mesalazine in patients with mild to moderate active ulcerative colitis after 8 weeks of treatment.

Phase

0.0 miles

Learn More »

Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])

This is a study of pembrolizumab (MK-3475, KEYTRUDA) in combination with lenvatinib (E7080) versus treatment of physician's choice (doxorubicin or paclitaxel) for the treatment of advanced endometrial cancer. Participants will be randomly assigned to receive either pembrolizumab and lenvatinib or treatment of physician's choice. The primary study hypothesis is that ...

Phase

0.0 miles

Learn More »

Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia

The purpose of this study is to evaluate the efficacy and safety of MT-5199 administered once daily for the treatment of Tardive Dyskinesia (TD) symptoms.

Phase

0.17 miles

Learn More »

Efficacy and Safety of MT-5547 in Patients With Osteoarthritis Accompanied by Moderate to Severe Pain

The blind will be maintained, including for the study sponsor, until the key code is opened after the data have been fixed for all subjects in Week 24. In addition, in order to eliminate any bias that could affect the study assessments, to the extent possible, the blind will be ...

Phase

0.17 miles

Learn More »

A Survey on Quetiapine Extended-release Tablets in Patients With Depression in Bipolar Disorder

This is a post-marketing use-result survey study required for products in Japan. The investigator will register the patient who have been taking this product for the first time within 14 days after the start of treatment (inclusive of the start day). For each of the registered patients (including withdrawals and ...

Phase N/A

0.17 miles

Learn More »